Immunotherapy is a cancer treatment that works by boosting the body’s immune system. Some patients achieve full remission, meaning all signs of their cancer have disappeared.
Departments, Centers, & Programs:
MGH Cancer Center, Bartlett Hall
55 Fruit Street
Boston, MA 02114
- MD, University of Missouri Hospitals and Clinics
- MD, University of Missouri School of Medicine
- Residency, Massachusetts General Hospital
- Residency, MGH
- Fellowship, Dana Farber Cancer Institute
- Fellowship, MGH
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
We are in the midst of an exciting revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system using novel therapies such as immune checkpoint inhibitors, we can reduce the amount of tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. However, these therapies are often limited by treatment-induced autoimmune adverse events. They affect nearly every organ system, ranging widely from minor rashes and fevers to severe gastrointestinal, pulmonary, or cardiac complications. Dr. Kerry Reynolds, along with Dr. Chloe Villani, and the Massachusetts General Hospital has taken a lead in this arena by altering our clinical practice model to provide expert multi-disciplinary care by creating the Severe Immunotherapy Complications Service. Importantly, this group is not just involved in the clinical care but they have banded together to set up infrastructure to empower specimen collection and facilitate translational research efforts, in order to understand the mechanisms driving immune-related adverse events (irAEs). Blood/tissue samples are systematically collected in an attempt to develop better therapies to treat autoimmune toxicities while maintaining anti-tumor immunity. The hope is that this will further our understanding of early mechanisms leading to autoimmune diseases and identify novel druggable targets with immunosuppressive potential. The Severe Immunotherapy Complications Service brings together expertise from a variety of clinical divisions and scientists across the institution to coordinate our care and tackle a critical problem facing many cancer patients today.
Molina GE, Zubiri L, et al, Reynolds KL. Temporal trends and outcomes among patients admitted for immune-related adverse events: A single-center retrospective cohort study from 2011-2018. Oncologist. 2021 Mar 3.
Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. Jan 2020;25(1):6-14.
Reynolds KL, Sullivan RJ, Fintelmann FJ, Mansour MK, England J. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. N Engl J Med. Mar 2020;382(12):1150-1159
Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. Apr 2019
Additional publications can be found - https://www.massgeneral.org/cancer-center/treatments-and-services/severe-immunotherapy-complications/
- Jun | 8 | 2021
In this interview Kerry Reynolds, MD chats with Yevgeniy (Eugene) Semenov, MD to learn about his work in cutaneous oncology and characterizing cutaneous immune-related adverse events.
- Press Release
- Apr | 12 | 2021
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
- Press Release
- Apr | 12 | 2021
Results will help guide care for many patients with advanced cancer.
- Nov | 5 | 2019
Over the last decade, immunotherapies have increasingly offered hope to thousands of patients with cancer; however, this does not come without its adverse events (AEs), according to Kerry Reynolds, MD.
- May | 18 | 2019
Mass General Cancer Center's Dr. Kerry Reynolds discusses the management of toxicities in an inpatient setting. This video was recorded on May 18, 2019 at the Annual Advances in Cancer Immunotherapy CME Course.